$6 isilky Helmet Visor Film Waterproof Motorcycle Helmet Lens Film Automotive Motorcycle Powersports $6 isilky Helmet Visor Film Waterproof Motorcycle Helmet Lens Film Automotive Motorcycle Powersports isilky Helmet discount Visor Film Motorcycle Lens Waterproof isilky Helmet discount Visor Film Motorcycle Lens Waterproof Automotive , Motorcycle Powersports,/homodoxian91366.html,Visor,Lens,www.gtconcrete.com,isilky,Helmet,Helmet,Film,$6,Film,Motorcycle,Waterproof Automotive , Motorcycle Powersports,/homodoxian91366.html,Visor,Lens,www.gtconcrete.com,isilky,Helmet,Helmet,Film,$6,Film,Motorcycle,Waterproof

isilky Helmet discount Visor Film Time sale Motorcycle Lens Waterproof

isilky Helmet Visor Film Waterproof Motorcycle Helmet Lens Film


isilky Helmet Visor Film Waterproof Motorcycle Helmet Lens Film


Product description


1. Safer: The full-frame universal helmet anti-fog film is effectively waterproof and anti-fog. With clearer vision, it is more secure for night driving.

2. Anti-glare: The anti-fog film better fit the helmet lens, reducing the glare phenomenon as the anti-fog film lens is not dense enough.

3. Resistance to physical hydrolysis: With special molecular structure, the anti-fog film will not reduce the anti-fog effect after being wetted by rain. You can continue to use it after rinsing with water and wiping it with a cloth.

4. Light transmittance is as high as 95%: With good light transmittance, the anti-fog film makes riding easy and reduces eye fatigue. It is sun-shading and eye protectivre, anti-ultraviolet radiation.

5. Wide application: Suitable for full helmets, half helmets, visor helmets, off-road helmets, not suitable for bubble helmets.


Name: Anti-fog Film for Motorcycle Helmet Lens

Material: PET

Size: about 23.5*7cm/2.95*2.75in

Packing List: 

1*Anti-fog Film for Helmet

isilky Helmet Visor Film Waterproof Motorcycle Helmet Lens Film

September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.


CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.


Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.